Editas Medicine (EDIT) Misses Q1 EPS by 13c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SPY
9. SWKS
10. FISV

Go back to Editas Medicine (EDIT) Misses Q1 EPS by 13c, Revenues Beat

Editas Medicine Announces First Quarter 2021 Results and Update

May 5, 2021 7:00 AM EDT

Strengthening Leadership by Adding Mark S. Shearman, Ph.D., as Chief Scientific Officer

Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end

RUBY trial of EDIT-301 for sickle cell disease active and recruiting

Preclinical ocular data presented at ARVO supports in vivo gene editing

Cash, cash equivalents, and marketable securities of $723 million as of March 31, 2021

CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading... More